This site is intended for healthcare professionals

MHLW (Japan)approved Rinvoq to treat Ankylosing Spondylitis.- AbbVie

Read time: 1 mins
Published:29th May 2022

Japan’s Ministry of Health, Labor and Welfare (MHLW) approved label expansion for AbbVie’s JAK inhibitor Rinvoq (upadacitinib).


Rinvoq was approved for the additional indication of ankylosing spondylitis, with its use limited to cases that cannot be adequately treated with existing therapies. This is the drug’s fourth indication in Japan, after rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.

Condition: Ankylosing Spondylitis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.